ECM
TEVA icon

EagleClaw Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

EagleClaw Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,750
Closed -$253K – 120
2018
Q3 		$253K Sell
11,750
-100
-0.8% -$2.32K 0.11% 107
2018
Q2 		$287K Sell
11,850
-500
-4% -$10.2K 0.14% 98
2018
Q1 		$212K Sell
12,350
-1,200
-9% -$23.4K 0.11% 109
2017
Q4 		$258K Sell
13,550
-1,925
-12% -$29K 0.13% 102
2017
Q3 		$271K Sell
15,475
-1,000
-6% -$22.5K 0.15% 98
2017
Q2 		$545K Hold
16,475
– – 0.32% 75
2017
Q1 		$529K Hold
16,475
– – 0.32% 77
2016
Q4 		$600K Sell
16,475
-1,000
-6% -$39.9K 0.38% 70
2016
Q3 		$804K Buy
17,475
+8,075
+86% +$421K 0.51% 65
2016
Q2 		$471K Sell
9,400
-1,200
-11% -$63.9K 0.31% 78
2016
Q1 		$567K Sell
10,600
-9,126
-46% -$535K 0.38% 67
2015
Q4 		$1.3M Sell
19,726
-500
-2% -$30.9K 0.86% 44
2015
Q3 		$1.14M Sell
20,226
-50
-0.2% -$3.24K 0.8% 46
2015
Q2 		$1.2M Sell
20,276
-350
-2% -$21.6K 0.77% 49
2015
Q1 		$1.28M Hold
20,626
– – 0.83% 46
2014
Q4 		$1.19M Hold
20,626
– – 0.78% 48
2014
Q3 		$1.11M Hold
20,626
– – 0.75% 51
2014
Q2 		$1.08M Hold
20,626
– – 0.73% 50
2014
Q1 		$1.09M Buy
+20,626
New +$953K 0.79% 48

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

EagleClaw Capital Management's TEVA Position: Q4 2018 in Review

EagleClaw Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 11,750 shares — an estimated $253K sold.

EagleClaw Capital Management first reported a position in TEVA in Q1 2014 and held it in 19 quarters. The position peaked at $1.3M in Q4 2015. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • EagleClaw Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • EagleClaw Capital Management sold 11,750 Teva Pharmaceuticals shares in Q4 2018, an estimated $253K.
  • EagleClaw Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 19 quarters.
  • EagleClaw Capital Management's Teva Pharmaceuticals position peaked at $1.3M in Q4 2015.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on EagleClaw Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.